No Big H1N1 Shipments Until December: Novartis - Healthcare * US * News * Story

Runway Angels
The superbowl of fashion shows, models walk down the runway at the 2009 Victoria's Secret Fashion Show.
The Richest Members of the US Congress
Recently, the Center for Responsive Politics found that there are 237 millionaires in the US Congress.
10 Tips to Get Out of Debt
Renowned financial author Gail Vaz-Oxlade takes a tough-love approach to helping couples in a financial crisis to face reality.

FEATURED QUIZZES

How Much Do You Know About Green?
Green has become part of our everyday lives. Green is everywhere-- energy, clothing, food, housing, transportation. It's a big business and a global business.
The Billionaire BFF's
Philanthropists. Bridge partners. Hockey players. Which responses are based on facts from Buffett's and Gates' real lives?
The Many Myths of Coca-Cola
Can you tell which statements are true, and which ones are just rumors?

SPECIAL REPORTS

Winterizing Your Portfolio
If 2009 was the winter of our discontent, will 2010 be a winter wonderland for investors? A lot depends on the recovery—or lack thereof.
Investor's Guide to Real Estate
Some even say the long-awaited recovery is here. Regardless, buyers and sellers alike can profit from our guide.
Alternative Investing
Stocks and bonds? Sure. But it's a big world out there for investors.

CNBC ON DIGG

No Big H1N1 Shipments Until December: Novartis

Published: Thursday, 22 Oct 2009 | 2:26 PM ET

Text Size

By: Mike Huckman
Reporter

Swiss drug giant Novartis says it has redeployed 300 workers from other divisions into its vaccines unit to meet what Chairman and CEO Dr. Daniel Vasella calls the "huge demand" for H1N1 shots.

"You can be assured we have put in everything we can to accelerate and maximize the output," Vasella told CNBC.

But he also acknowledged the company is hamstrung to a certain extent by "physical constraints of production capacity" and low H1N1 vaccine manufacturing yields that are as little as one-fifth the normal yield.

As a result, Vasella said that the company will not be able to ship "large quantities" of the vaccine until around the end of December and that some of the approximately 100 million doses Novartis [NVS Loading... () ] plans to make may not arrive until the first quarter of next year. Many states, municipalities, clinics and physicians are reporting H1N1 vaccine shortages.

Dr. Vasella also stood by the vaccine's safety, claiming that it has been studied more extensively than any seasonal flu vaccine. More than 8,000 people have been enrolled in Novartis' H1N1 vaccine clinical trials.